Share
When you hear the words Alzheimer's disease, what do you think of? The truth is, the picture most of us have of the disease is incomplete. Alzheimer's disease doesn't start when someone starts to lose their memory. It actually starts years – sometimes decades – earlier. The Rethinking Alzheimer's Disease Podcast is an engaging, narrative-style podcast miniseries for those curious or motivated to learn about Alzheimer’s disease. Perhaps you have a family member with Alzheimer’s disease, or ca ...
…
continue reading
Manage episode 520899184 series 2835025
Content provided by Ira Pastor. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Ira Pastor or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.
Dr. Carina Kern, Ph.D. is the CEO of LinkGevity ( https://www.linkgevity.com/ ), an AI-powered biotech company driving innovation in drug discovery for aging and resilience loss.
Dr. Kern has developed a new Blueprint Theory of Aging, which takes an integrative approach to understanding aging, combining evolutionary theory, genetics, molecular mechanisms and medicine, and is used to structure LinkGevity’s AI.
Dr. Kern’s labs are based at the Babraham Research Campus, affiliated with the University of Cambridge and her research has led to the development of a first-in-class necrosis inhibitor targeting cellular degeneration (Anti-Necrotic™). This novel therapeutic is ready to begin Phase II clinical trials later this year, as a potential breakthrough treatment for aging, with UK Government, Francis Crick Institute KQ labs, and European Union (Horizon) support.
The Anti-Necrotic™ has also been selected as one of only 12 global innovations for NASA’s Space-Health program, recognizing its potential to mitigate accelerated aging in astronauts on long-duration space missions.
Dr. Kern has held academic and leadership roles in interdisciplinary networks, including serving as President of the London Evolutionary Research Network and Co-Chair of the CleanTech Business Challenge, an initiative co-led by University College London and the London Business School.
Dr. Kern completed her PhD at UCL Institute of Healthy Ageing.
#CarinaKern #LinkGevity #BlueprintTheoryOfAging #BiologicalResilience #UniversityOfCambridge #BabrahamResearchCampus #CellularDegeneration #NecrosisInhibitor #AntiNecrotic #CaenorhabditisElegans #UCLInstituteOfHealthyAgeing #Senescence #Apoptosis #CellDeath #Necroptosis #Pyroptosis #Ferroptosis #PathoPathways #Gerotherapeutics #RyanodineReceptorInhibitors #CellPermeantCalciumChelators #LINK001 #AcuteKidneyInjury #SpaceMedicine #Exposome #Longevity
#ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #ViralPodcast #STEM #Innovation #Technology #Science #Research
725 episodes
))
